At present, some animal models have confirmed that short‐term treatment with monoclonal antibodies of ANGPTL4 can reduce TG and LDL, thus providing strong evidence for the application of ANGPTL4 targeted therapy in patients with CAD.26, 36. This evidence concerns the gene ANGPTL4 and coronary artery disorder.